Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Keros Therapeutics, Inc.KROS · Entity 6242 | Director | June 04, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Keros Therapeutics, Inc.
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,958 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Sale · Disposed 2,625 · Balance 10,958 F1: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.61 to $10.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 150,047 |
Reported balance
Holding disclosure · report date 2026-06-04 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 150,047 F3: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 102,233 |
Reported balance
Holding disclosure · report date 2026-06-04 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 102,233 F4: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.61 to $10.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I.
F4: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2021 Filed Feb 16, 2021 22:50 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 985 | $62.52 | $61,582.20 |
DisclosureSEC source: 0001209191-21-010884 · doc4.xml · nonDerivative · entry 17 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 677,008 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.75 to $62.68 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| February 12, 2021 Filed Feb 16, 2021 22:50 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 913 | $61.03 | $55,720.39 |
DisclosureSEC source: 0001209191-21-010884 · doc4.xml · nonDerivative · entry 16 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 452,132 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.74 to $61.60 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| February 12, 2021 Filed Feb 16, 2021 22:50 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,397 | $61.03 | $85,258.91 |
DisclosureSEC source: 0001209191-21-010884 · doc4.xml · nonDerivative · entry 15 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 677,993 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.74 to $61.60 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| February 12, 2021 Filed Feb 16, 2021 22:50 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 833 | $60.20 | $50,146.60 |
DisclosureSEC source: 0001209191-21-010884 · doc4.xml · nonDerivative · entry 14 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 453,045 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.74 to $60.73 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| February 12, 2021 Filed Feb 16, 2021 22:50 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,278 | $60.20 | $76,935.60 |
DisclosureSEC source: 0001209191-21-010884 · doc4.xml · nonDerivative · entry 13 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 679,390 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.74 to $60.73 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 22:50 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 35 | $67.98 | $2,379.30 |
DisclosureSEC source: 0001209191-21-010884 · doc4.xml · nonDerivative · entry 12 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 453,878 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.59 to $68.05 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 22:50 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 53 | $67.99 | $3,603.47 |
DisclosureSEC source: 0001209191-21-010884 · doc4.xml · nonDerivative · entry 11 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 680,668 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.59 to $68.05 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 22:50 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 206 | $66.65 | $13,729.90 |
DisclosureSEC source: 0001209191-21-010884 · doc4.xml · nonDerivative · entry 10 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 453,913 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.36 to $67.09 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 22:50 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 316 | $66.65 | $21,061.40 |
DisclosureSEC source: 0001209191-21-010884 · doc4.xml · nonDerivative · entry 9 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 680,721 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.36 to $67.09 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 22:50 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,575 | $65.80 | $103,635.00 |
DisclosureSEC source: 0001209191-21-010884 · doc4.xml · nonDerivative · entry 8 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 454,119 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.32 to $66.30 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 22:50 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 2,418 | $65.80 | $159,104.40 |
DisclosureSEC source: 0001209191-21-010884 · doc4.xml · nonDerivative · entry 7 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 681,037 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.32 to $66.30 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 22:50 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 952 | $64.87 | $61,756.24 |
DisclosureSEC source: 0001209191-21-010884 · doc4.xml · nonDerivative · entry 6 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 455,694 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.32 to $65.25 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 22:50 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,461 | $64.87 | $94,775.07 |
DisclosureSEC source: 0001209191-21-010884 · doc4.xml · nonDerivative · entry 5 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 683,455 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.32 to $65.25 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 22:50 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,526 | $63.83 | $97,404.58 |
DisclosureSEC source: 0001209191-21-010884 · doc4.xml · nonDerivative · entry 4 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 456,646 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.28 to $64.26 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 22:50 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 2,335 | $63.83 | $149,043.05 |
DisclosureSEC source: 0001209191-21-010884 · doc4.xml · nonDerivative · entry 3 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 684,916 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.28 to $64.26 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 22:50 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 270 | $62.79 | $16,953.30 |
DisclosureSEC source: 0001209191-21-010884 · doc4.xml · nonDerivative · entry 2 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 458,172 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.28 to $63.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8) (9), (10), (11), (12), (13) and (14). F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 22:50 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 414 | $62.79 | $25,995.06 |
DisclosureSEC source: 0001209191-21-010884 · doc4.xml · nonDerivative · entry 1 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 687,251 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.28 to $63.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8) (9), (10), (11), (12), (13) and (14). F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:13 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionSeries C Preferred Stock · Derivative | 44,676 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024227 · doc4.xml · derivative · entry 12 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 44,676 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F3 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:13 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionSeries C Preferred Stock · Derivative | 67,015 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024227 · doc4.xml · derivative · entry 11 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 67,015 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:13 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionSeries B-1 Preferred Stock · Derivative | 137,308 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024227 · doc4.xml · derivative · entry 10 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 137,308 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F3 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:13 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionSeries B-1 Preferred Stock · Derivative | 205,962 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024227 · doc4.xml · derivative · entry 9 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 205,962 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:13 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionSeries A Preferred Stock · Derivative | 184,305 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024227 · doc4.xml · derivative · entry 8 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 184,305 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F3 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:13 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionSeries A Preferred Stock · Derivative | 276,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024227 · doc4.xml · derivative · entry 7 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 276,459 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:13 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionCommon Stock | 44,676 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-024227 · doc4.xml · nonDerivative · entry 6 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 458,442 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F3 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:13 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionCommon Stock | 67,015 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-024227 · doc4.xml · nonDerivative · entry 5 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 687,665 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:13 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionCommon Stock | 137,308 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-024227 · doc4.xml · nonDerivative · entry 4 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 413,766 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F3 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:13 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionCommon Stock | 205,962 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-024227 · doc4.xml · nonDerivative · entry 3 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 620,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:13 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionCommon Stock | 184,305 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-024227 · doc4.xml · nonDerivative · entry 2 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 276,458 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F3 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:13 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionCommon Stock | 276,459 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-024227 · doc4.xml · nonDerivative · entry 1 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 414,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| April 13, 2020 Filed Jan 20, 2023 21:32 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | PurchaseCommon Stock | 1,191 | $20.98 | $24,987.18 |
DisclosureSEC source: 0001209191-23-004279 · doc4.xml · nonDerivative · entry 1 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,191 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.